A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was: which patients might be suitable for a transcatheter closure (TCC) of their postinfarction ventricular septal rupture (VSR) rather than immediate surgery? Thirty papers were found using the reported search, five of which represented the best evidence to answer the clinical question. The main limitations were the paucity of level 1 evidence on this topic. Only one study provided a prospective series as part of a registry; the remaining were retrospective cohort analyses. Although multivariate analysis may adequately control for measurable biases, unmeasured bias may still exist and influence the results. All studies agreed that timing of intervention is critical in determining the outcome. Patient's preoperative haemodynamic status was a major determinant of postoperative survival. Successful outcome after TCC was in patients with simple defects, -15 mm in diameter that were in the sub-acute ()3.5 weeks) or chronic stage following acute myocardial infarct (AMI). Procedural success rate varied from 73.6% to 91%. Three of five studies looking at TCC closure concluded that procedural success does not necessarily translate to improved outcome. TCC in the acute setting (within four weeks of AMI) led to a high mortality (18%-65%) and increased incidence of complications (up to 41%). These included device embolization, major residual shunting, left ventricular rupture and malignant arrhythmias. One recent study correlated mortality to residual VSR wodds ratio (OR) 0.071, Ps0.02x, increased time from myocardial infarction to VSR diagnosis (OR 0.757, Ps0.04) and increased time from VSR diagnosis to treatment (OR 0.758, Ps0.04). The overwhelming recommendations were for immediate surgical intervention in cases of large VSR G15 mm or where another indication for surgery exists. Three of five studies commented on a lack of a suitable device for PIVSR closure, with highest technical success with the Amplatzer device. In conclusion, small or medium PIVSR (-15 mm) can be treated definitively with Amplatzer closure in the sub-acute and chronic setting with comparable mortality to surgery. In the acute setting where surgery is deemed prohibitive TCC may provide a bridge to stabilize patients with shunt reduction, prior to surgery. The standard of treatment in large defects and PIVSRs in the acute setting remains early surgery.
Introduction
A best evidence topic was constructed according to a structured protocol. This is fully described in ICVTS w1x.
Three-part question
In wpatients with a postinfarct VSRx might wa septal occluder devicex give equivalent results to wsurgical closurex in terms of wmortalityx?
Clinical scenario
You have been asked to review a 75-year-old female who has been diagnosed with an inferior acute myocardial infarct (AMI). Coronary angiography demonstrated a tight right coronary ostial stenosis. This was pre-dilated by balloon angioplasty and stented. Hours later she developed clinical signs of right sided heart failure and a worsening *Corresponding author. Tel.: q44 02-71880980; fax: q44 02-71881006. E-mail address: rizwanattia@doctors.org.uk (R. Attia). metabolic acidosis. An echocardiogram revealed a 15-mm infero-basal ventricular septal rupture (VSR). Her systolic pressure was 90 mmHg on 20 mgykgymin of Dobutamine, electrocardiogram indicated a resolving inferior myocardial infarction (MI). The cardiologist would like to discuss with you the role of an Amplatzer device in this patient. You decide to look up the evidence on the topic.
Search strategy
Medline search 1950-April 2010 was performed using OVID interface wpostinfarct ventricularycardiac septal rupturex OR wpostinfarct ventricularycardiac septal rupture.mpx AND wseptal occluder devicex OR wpercutaneousx OR wtranscatheterx OR wendovascularx.
Search outcome
Thirty papers were identified, including one review. Of these five papers represented the best evidence on the topic (Table 1) . Downloaded from https://academic.oup.com/icvts/article-abstract/11/5/626/656504 by guest on 13 March 2019 Studies overlapping patient groups from the same institution and not declaring clinical outcomes were excluded. Studies with a heterogeneous aetiology to VSR and pooled results were excluded. Case reports and small series of -5 patients were not enrolled. Primary outcome of interest was early and overall mortality rates. Secondary outcome of interest was procedural success and device complications.
Results

Maltais et al., compared 51 patients, 39 operative cases with 12 cases undergoing transcatheter closure (TCC).
Treatment was decided by a multidisciplinary team. Patients with postinfarction ventricular septal rupture (PIVSR) )15 mm had immediate surgery (David endomyocardial closure), whilst patients with anatomically suitable small PIVSR were considered for the Amplatzer device. There were no significant differences between the two groups for demographics, co-morbidities, preoperative state, time between AMI and PIVSR diagnosis, time to surgery and anatomical location of VSR. There was no difference in overall mortality (surgery 33% vs. TCC 42% Ps0.056) and residual VSR (surgery 13.5% vs. TCC 8.3% Ps0.63). VSR diameter as expected was larger in the surgical group (12.4"4.5 mm) vs. TCC (10"2.6 mm)
Ps0
.04. Multivariate analysis demonstrated in-hospital mortality correlated to residual VSR wodds ratio (OR) 0.071 (0.007-0.690) Ps0.02x, time from MI to diagnosis wOR 0.7557 (0.058-0.988) Ps0.04x and time from diagnosis to intervention wOR 0.758 (0.580-0.992) Ps0.04x. The authors suggest a new treatment algorithm where acute smally medium VSRs are initially treated with TCC with the Amplatzer device allowing myocardial fibrosis, facilitating delayed surgical correction if significant residual VSR persists. Large (G15 mm) VSR should undergo immediate surgical correction because these patients are likely to experience device embolization or residual VSR. In this series the patient with the largest VSR undergoing TCC died due to early device embolization in the pulmonary artery.
Twenty-nine consecutive patients underwent TCC closure under Thiele et al. w3x . The 30-day mortality was 65% with strong correlation with cardiogenic shock (88% vs. 38%, PF0.001). The overall mortality was 69% with infection of the device causing a late death. The median time from AMI to diagnosis was two days with a further day to intervention winter-quartile range (IQR) 1-3 daysx. Procedure-related complications included major residual shunting, left ventricular rupture and device embolization, occurring in 41% of patients. The mean reduction in shunt (Qp; Qs) was 3.3 (IQR 2.3-3.8) to 1.4 (IQR 1.2-1.7; Ps0.001). Despite the minimally-invasive nature of TCC, mortality was very high, Downloaded from https://academic.oup.com/icvts/article-abstract/11/5/626/656504 by guest on 13 March 2019 mainly attributed to disease severity and comorbidities. Authors conclude this may also be related to current suboptimal interventional techniques and available devices. Bialkowski et al., undertook 19 TCC, primarily 15y19 (79%) in the sub-acute phase (3.5-12 weeks postinfarct). These were simple direct shunts in 68%. Successful implantation in 14y19 (73%) was achieved: 11y14 sub-acute PIVSR, one chronic PIVSR and two postsurgical. There were none in acute patients. Large defects could not be closed as they could not be transversed with the wire, the sheath kinked or septal occluders freely transversed defects necessitating surgery. The 30-day mortality was 4y14 (28.5%). TCC during the acute phase was a high-risk procedure with highlikelihood of failure. The sub-acuteychronic group have thinner, firmer edges of VSR, allowing better fit of TCC device. The current device is best suited to simple small to medium defects. Even with initial immediate satisfactory results, severe left ventricular failure and multi-system organ failure resulted in poor outcome.
Holzer et al., reported results from a US registry of 18 patients in whom the procedural success rate was 89%. The 30-day mortality was 28% with long-term mortality of 61% at a median of 332 days. Residual VSR persisted in 8y11 (73%) with moderate shunt in 2y11 (18%). The authors commented that residual shunt was likely through the fabric of the device and manufacturers are now adding an additional layer of fabric to prevent this. They argue that even after surgical closure the incidence of shunting can be as high as 37% requiring a secondary procedure. Demkow and colleagues reported the series of 11 cases that demonstrated successful device implantation in all but one patient (26 mm occluder in 16 mm defect). The remaining 10 patients had 8-21 mm defects (mean 14.3) with 11-30 mm (mean 19.3) devices. Successful implantation did not clinically succeed in patients with the acute septal rupture, where there were 2y2 deaths. In 8y10 in whom the procedure was performed late (3.5-56 weeks) after AMI, the defect was either completely closed or the shunt was insignificant with clinical improvement. Followup from 1 to 62 months (mean 25.5) demonstrated New York Heart Association (NYHA) I or II class symptoms.
Clinical bottom line
At present early definitive surgical correction remains the gold standard for PIVSR. TCC has a role in selected patients with simple defects that are -15 mm, in the sub-acutey chronic ()3.5 weeks postAMI) setting where an Amplatzer device may provide definitive treatment. In some patients who are too unwell to be expected to survive an operation, an Amplatzer device may provide stabilization before urgent surgery is undertaken.
